BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fujiwara N, Kubota N, Crouchet E, Koneru B, Marquez CA, Jajoriya AK, Panda G, Qian T, Zhu S, Goossens N, Wang X, Liang S, Zhong Z, Lewis S, Taouli B, Schwartz ME, Fiel MI, Singal AG, Marrero JA, Fobar AJ, Parikh ND, Raman I, Li QZ, Taguri M, Ono A, Aikata H, Nakahara T, Nakagawa H, Matsushita Y, Tateishi R, Koike K, Kobayashi M, Higashi T, Nakagawa S, Yamashita YI, Beppu T, Baba H, Kumada H, Chayama K, Baumert TF, Hoshida Y. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. Sci Transl Med 2022;14:eabo4474. [PMID: 35731891 DOI: 10.1126/scitranslmed.abo4474] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Teng PC, Huang DQ, Lin TY, Noureddin M, Yang JD. Diabetes and Risk of Hepatocellular Carcinoma in Cirrhosis Patients with Nonalcoholic Fatty Liver Disease. Gut Liver 2023;17:24-33. [PMID: 36530125 DOI: 10.5009/gnl220357] [Reference Citation Analysis]
2 Kaur S, Kidambi S, Ortega-Ribera M, Thuy LTT, Nieto N, Cogger VC, Xie WF, Tacke F, Gracia-Sancho J. In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations. Cell Mol Gastroenterol Hepatol 2022;15:559-71. [PMID: 36442812 DOI: 10.1016/j.jcmgh.2022.11.008] [Reference Citation Analysis]
3 Rasha F, Paul S, Simon TG, Hoshida Y. Hepatocellular Carcinoma Chemoprevention with Generic Agents. Semin Liver Dis 2022;42:501-13. [PMID: 36104114 DOI: 10.1055/a-1942-6693] [Reference Citation Analysis]
4 Hoogerland JA, Staels B, Dombrowicz D. Immune–metabolic interactions in homeostasis and the progression to NASH. Trends in Endocrinology & Metabolism 2022;33:690-709. [DOI: 10.1016/j.tem.2022.07.001] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
5 Arvanitakis K, Koufakis T, Kotsa K, Germanidis G. How Far beyond Diabetes Can the Benefits of Glucagon-like Peptide-1 Receptor Agonists Go? A Review of the Evidence on Their Effects on Hepatocellular Carcinoma. Cancers 2022;14:4651. [DOI: 10.3390/cancers14194651] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Lee YT, Fujiwara N, Yang JD, Hoshida Y. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology 2022. [PMID: 36082510 DOI: 10.1002/hep.32779] [Reference Citation Analysis]